October 21st 2024
The Global Organization for EPA and DHA Omega-3s’ vice president of regulatory and scientific affairs talks about recent class actions and why they are without merit.
Peer-reviewed article highlights methodology of GOED’s new clinical study database
July 8th 2022The paper provides transparency into how the database collects and processes the research it compiles, insights into the design of its graphical user interface, as well as the database’s strengths and limitations.
Pentadecanoic acid may offer more benefits than EPA, says newly published study
May 26th 2022A new study shows that an odd-chain saturated fat, called Pentadecanoic acid (C:15:0), may be healthier, safer, and more effective for supporting cellular health than the leading omega-3 fatty acid, eicosapentaenoic acid (EPA).
GC Rieber VivoMega to make significant investment in facility expansion
May 6th 2022GC Rieber VivoMega has announced a five-year $75 million investment plan to build a new facility at its manufacturing campus. The new facility will enable the company to more than double the output of its high-end triglyceride form of omega-3s EPA and DHA.
Vitamin D and omega-3 supplementation may help reduce risk of autoimmune disease, says recent study
February 1st 2022The vitamin D and omega-3 trial (VITAL) is a nationwide, randomized, double-blind, placebo-controlled trial with a two-by-two factorial design. The study consisted of 25,871 participants, 12,786 of which were men aged 50 or over, and 13,085 of which were women aged 55 or over.
Retailing dietary supplements and natural products in 2022: An opportunity for improvement
February 1st 2022COVID will continue to impact supplement retailing. But instead of scrambling to adjust, brands have the opportunity to hone their omnichannel strategy and improve long-distance retail relationships.